A review of mechanisms of circumvention and modulation of chemotherapeutic drug resistance

Current Cancer Drug Targets

Volumn 9, Issue 3, 2009, Pages 273-280

  O'Connor, R ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Apoptosis; Circumvention; MDR; Pharmacodynamic resistance; Pharmacokinetic resistance; Resistance; Resistance pharmacology

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; ELACRIDAR; EPIRUBICIN; IMATINIB; IRINOTECAN; LIPOSOME; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; O 6 BENZYLGUANINE; OBLIMERSEN; SULINDAC; TEMOZOLAMIDE; TEMOZOLOMIDE; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VERAPAMIL;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER RESEARCH; CANCER RESISTANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DNA REPAIR; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENCAPSULATION; HUMAN; MELANOMA; MULTIDRUG RESISTANCE; PHENOTYPE; REVIEW; STEM CELL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SURVIVORS;

EID: 65649087840     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909788166583     Document Type: Review

References (80)

1. Cox, M. C.; Dan, T. D.; Swain, S. M. Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin. Emerg. Drugs 2006, 11, 489-501. (Pubitemid 44386372)
2. O'Connor, R.; Clynes, M.; Dowling, P.; O'Donovan, N.; O'Driscoll, L. Drug resistance in cancer - searching for mechanisms, markers and therapeutic agents. Expert Opin. Drug Metab. Toxicol. 2007, 3, 805-817. (Pubitemid 350285336)
3. O'Connor, R. The pharmacology of cancer resistance. Anticancer Res. 2007, 27, 1267-1272. (Pubitemid 46813088)
4. Fojo, T.; Coley, H. M. The role of efflux pumps in drug-resistant metastatic breast cancer: new insights and treatment strategies. Clin. Breast Cancer 2007, 7, 749-756. (Pubitemid 350086119)
5. Curtin, N. Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opin. Ther. Targets 2007, 11, 783-799. (Pubitemid 46908271)
6. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5, 275-284. (Pubitemid 40488633)
7. Clarke, R.; Leonessa, F.; Trock, B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin. Oncol. 2005, 32, S9-S15. (Pubitemid 41785441)
8. Matheny, C. J.; Lamb, M. W.; Brouwer, K. R.; Pollack, G. M. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001, 21, 778-796. (Pubitemid 32606791)
9. Thomas, H.; Coley, H. M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10, 159-165. (Pubitemid 36437822)
10. Luqmani, Y. A. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract. 2005, 14(Suppl. 1), 35-48. (Pubitemid 41161048)
11. Tsuruo, T.; Naito, M.; Tomida, A.; Fujita, N.; Mashima, T.; Sakamoto, H.; Haga, N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94, 15-21. (Pubitemid 36575852)
12. Kruijtzer, C. M.; Beijnen, J. H.; Rosing, H.; ten Bokkel Huinink, W. W.; Schot, M.; Jewell, R. C.; Paul, E. M.; Schellens, J. H. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 2002, 20, 2943-2950.
13. Feldmann, H. J.; Molls, M.; Vaupel, P. Blood flow and oxygenation status of human tumors - Clinical investigations. Strahlenther. Onkol. 1999, 175, 1-9. (Pubitemid 29038345)
14. Tredan, O.; Galmarini, C. M.; Patel, K.; Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99, 1441-1454.
15. Jang, S. H.; Wientjes, M. G.; Lu, D.; Au, J. L. S. Drug delivery and transport to solid tumors. Pharm. Res. 2003, 20, 1337-1350. (Pubitemid 37164040)
16. Martinez-Sanchez, G.; Giuliani, A. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development. J. Exp. Clin. Cancer Res. 2007, 26, 39-50. (Pubitemid 46656031)
17. Trueba, G. P.; Sanchez, G. M.; Giuliani, A. Oxygen free radical and antioxidant defense mechanism in cancer. Front. Biosci. 2004, 9, 2029-2044.
18. Wu, J.; Lu, Y.; Lee, A.; Pan, X.; Yang, X.; Zhao, X.; Lee, R. J. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 2007, 10, 350-357. (Pubitemid 350065179)
19. Zhou, J.; Schmid, T.; Schnitzer, S.; Brune, B. Tumor hypoxia and cancer progression. Cancer Lett. 2006, 237, 10-21.
20. Michael, M.; Doherty, M. M. Tumoral drug metabolism: Overview and its implications for cancer therapy. J. Clin. Oncol. 2005, 23, 205-229. (Pubitemid 41702640)
21. Choi, B. H.; Kim, C. G.; Lim, Y.; Shin, S. Y.; Lee, Y. H. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008, 259, 111-118. (Pubitemid 350235095)
22. Kapp, T.; Muller, S.; Gust, R. Dinuclear alkylamine platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum (II): influence of endocytosis and copper and organic cation transport systems on cellular uptake. Chem. Med. Chem. 2006, 1, 560-564.
23. Assaraf, Y. G. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007, 26, 153-181. (Pubitemid 46452189)
24. Juliano, R. L.; Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 1976, 455, 152-162.
25. Leonard, R. C.; Lind, M.; Twelves, C.; Coleman, R.; van Belle, S.; Wilson, C.; Ledermann, J.; Kennedy, I.; Barrett-Lee, P.; Perren, T.; Verrill, M.; Cameron, D.; Foster, E.; Yellowlees, A.; Crown, J. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J. Natl. Cancer Inst. 2004, 96, 1076-1083. (Pubitemid 39172409)
26. Kantarjian, H. M.; Talpaz, M.; Giles, F.; O'Brien, S.; Cortes, J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med. 2006, 145, 913-923.
27. Cleary, I.; Doherty, G.; Moran, E.; Clynes, M. The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. Pharmacol. 1997, 53, 1493-1502. (Pubitemid 27356122)
28. Duvvuri, M.; Krise, J. P. Intracellular drug sequestration events associated with the emergence of multidrug resistance: A mechanistic review. Front. Biosci. 2005, 10, 1499-1509. (Pubitemid 40529015)
29. Noguchi, S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 2006, 97, 813-820. (Pubitemid 44151259)
30. Rodriguez-Antona, C.; Ingelman-Sundberg, M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006, 25, 1679-1691.
31. Fulda, S.; Debatin, K. M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25, 4798-4811. (Pubitemid 44187627)
32. Daly, A. K. Individualized drug therapy. Curr. Opin. Drug Discov. Dev. 2007, 10, 29-36. (Pubitemid 46438254)
33. Rebbaa, A. Targeting senescence pathways to reverse drug resistance in cancer. Cancer Lett. 2005, 219, 1-13. (Pubitemid 40203165)
34. Zaremba, T.; Curtin, N. J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 2007, 7, 515-523.
35. Ross, D. D.; Yang, W.; Abruzzo, L. V.; Dalton, W. S.; Schneider, E.; Lage, H.; Dietel, M.; Greenberger, L.; Cole, S. P.; Doyle, L. A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst. 1999, 91, 429-433. (Pubitemid 29128278)
36. Gonzalez-Angulo, A. M.; Morales-Vasquez, F.; Hortobagyi, G. N. Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 2007, 608, 1-22.
37. Crown, J. Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer. Eur. J. Cancer 1997, 33(Suppl. 7), S15-S19. (Pubitemid 127704325)
38. Crown, J. Evolution in the treatment of advanced breast cancer. Semin. Oncol. 1998, 25, 12-17. (Pubitemid 28562733)
39. Crown, J. Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer. Lancet 2004, 364, 1299-1300. (Pubitemid 39335812)
40. Lengfelder, E.; Hehlmann, R. Intensive combination chemotherapy in treatment of CML. Bone Marrow Transplant. 1996, 17(Suppl. 3), S55-S57. (Pubitemid 26181610)
41. Figgitt, D. P.; Wiseman, L. R. Docetaxel: an update of its use in advanced breast cancer. Drugs 2000, 59, 621-651. (Pubitemid 30213866)
42. Bunn, P. A., Jr.; Thatcher, N. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction. Oncologist 2008, 13(Suppl. 1), 1-4.
43. Cano-Gauci, D. F.; Riordan, J. R. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem. Pharmacol. 1987, 36, 2115-2123. (Pubitemid 17101723)
44. Nobili, S.; Landini, I.; Giglioni, B.; Mini, E. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 2006, 7, 861-879.
45. Perez-Tomas, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 2006, 13, 1859-1876.
46. Johnson, W. W. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods Find. Exp. Clin. Pharmacol. 2002, 24, 501-514. (Pubitemid 35402855)
47. Modok, S.; Mellor, H. R.; Callaghan, R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol. 2006, 6, 350-354. (Pubitemid 44026037)
48. Fox, E.; Maris, J. M.; Widemann, B. C.; Goodspeed, W.; Goodwin, A.; Kromplewski, M.; Fouts, M. E.; Medina, D.; Cohn, S. L.; Krivoshik, A.; Hagey, A. E.; Adamson, P. C.; Balis, F. M. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. Clin. Cancer Res. 2008, 14, 1111-1115.
49. Denduluri, N.; Swain, S. M. Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin. Investig. Drugs 2008, 17, 423-435.
50. Ferlini, C.; Gallo, D.; Scambia, G. New taxanes in development. Expert Opin. Investig. Drugs 2008, 17, 335-347.
51. Cole, S. P.; Bhardwaj, G.; Gerlach, J. H.; Mackie, J. E.; Grant, C. E.; Almquist, K. C.; Stewart, A. J.; Kurz, E. U.; Duncan, A. M.; Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654. (Pubitemid 23012438)
52. Leslie, E. M.; Deeley, R. G.; Cole, S. P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 2005, 204, 216-237. (Pubitemid 40552845)
53. Robey, R. W.; Polgar, O.; Deeken, J.; To, K. W.; Bates, S. E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007, 26, 39-57. (Pubitemid 46452182)
54. Kuppens, I. E.; Witteveen, E. O.; Jewell, R. C.; Radema, S. A.; Paul, E. M.; Mangum, S. G.; Beijnen, J. H.; Voest, E. E.; Schellens, J. H. A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin. Cancer Res. 2007, 13, 3276-3285. (Pubitemid 46944913)
55. Munoz, M.; Henderson, M.; Haber, M.; Norris, M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007, 59, 752-757.
56. O'Connor, R.; Heenan, M.; Connolly, L.; Larkin, A.; Clynes, M. Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res. 2004, 24, 457-464. (Pubitemid 38623120)
57. Duffy, C.; Elliott, C.; O'Connor, R.; Heenan, M.; Coyle, S.; Cleary, I.; Kavanagh, K.; Verhaegen, S.; O'Loughlin, C.; NicAmhlaoibh, R.; Clynes, M. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur. J. Cancer 1998, 34, 1250-1259. (Pubitemid 28342118)
58. Tawbi, H. A.; Kirkwood, J. M. Management of metastatic melanoma. Semin. Oncol. 2007, 34, 532-545. (Pubitemid 350236308)
59. Larkin, A.; O'Driscoll, L.; Kennedy, S.; Purcell, R.; Moran, E.; Crown, J.; Parkinson, M.; Clynes, M. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int. J. Cancer 2004, 112, 286-294. (Pubitemid 39244369)
60. Galimberti, S.; Testi, R.; Guerrini, F.; Fazzi, R.; Petrini, M. The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia. J. Chemother. 2003, 15, 374-379. (Pubitemid 36904323)
61. O'Driscoll, L.; Walsh, N.; Larkin, A.; Ballot, J.; Ooi, W. S.; Gullo, G.; O'Connor, R.; Clynes, M.; Crown, J.; Kennedy, S. MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma. Anticancer Res. 2007, 27, 2115-2120. (Pubitemid 47228044)
62. Alison, M. R.; Murphy, G.; Leedham, S. Stem cells and cancer: a deadly mix. Cell Tissue Res. 2008, 331, 109-124. (Pubitemid 350265500)
63. Ozvegy-Laczka, C.; Hegedus, T.; Varady, G.; Ujhelly, O.; Schuetz, J. D.; Varadi, A.; Keri, G.; Orfi, L.; Nemet, K.; Sarkadi, B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 2004, 65, 1485-1495. (Pubitemid 38668306)
64. Burger, H.; Nooter, K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 2004, 3, 1502-1505. (Pubitemid 40521401)
65. O'Connor, R.; O'Leary, M.; Ballot, J.; Collins, C. D.; Kinsella, P.; Mager, D. E.; Arnold, R. D.; O'Driscoll, L.; Larkin, A.; Kennedy, S.; Fennelly, D.; Clynes, M.; Crown, J. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother. Pharmacol. 2006, 59, 79-87.
66. Huwyler, J.; Drewe, J.; Krahenbuhl, S. Tumor targeting using liposomal antineoplastic drugs. Int. J. Nanomed. 2008, 3, 21-29.
67. Fenske, D. B.; Cullis, P. R. Liposomal nanomedicines. Expert. Opin. Drug Deliv. 2008, 5, 25-44.
68. Labialle, S.; Gayet, L.; Marthinet, E.; Rigal, D.; Baggetto, L. G. Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem. Pharmacol. 2002, 64, 943-948. (Pubitemid 35232268)
69. Kaszubiak, A.; Holm, P. S.; Lage, H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Int. J. Oncol. 2007, 31, 419-430.
70. Arora, A.; Seth, K.; Kalra, N.; Shukla, Y. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol. Toxicol. Appl. Pharmacol. 2005, 202, 237-243. (Pubitemid 40164277)
71. Marguerite, V.; Beri-Dexheimer, M.; Ortiou, S.; Gueant, J. L.; Merten, M. Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cell. Physiol. Biochem. 2007, 20, 967-976. (Pubitemid 350059739)
72. Debatin, K. M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. 2004, 53, 153-159. (Pubitemid 38328037)
73. Cepeda, V.; Fuertes, M.; Castilla, J.; Alonso, C.; Quevedo, C.; Soto, M.; Perez, J. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Pat. Anticancer Drug Discov. 2006, 1, 39-53.
74. Plummer, E. Inhibition of poly(ADP-ribose) pollyrnerase in cancer. Curr. Opin. Pharmacol. 2006, 6, 364-368.
75. Ratnam, K.; Low, J. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 2007, 13, 1383-1388. (Pubitemid 46450426)
76. Gerson, S. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 2004, 4, 296-307. (Pubitemid 38525285)
77. Gajewski, T.; Sosman, J.; Gerson, S.; Liu, L.; Dolan, E.; Lin, S.; Vokes, E. Phase II trial of the O-6-alkylguanine DNA alkyltransferase inhibitor O-6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin. Cancer Res. 2005, 11, 7861-7865. (Pubitemid 41611631)
78. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium. Drugs R D 2007, 8, 321-334.
79. Schimmer, A. D. Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia. Curr. Treat. Options Oncol. 2007, 8, 277-286.
80. Letai, A. G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 2008, 8, 121-132.